Ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma (ID3816)

£787.5K GBP

Funder	National Institute for Health Research
Recipient Organization	University of York
Country	United Kingdom
Start Date	May 26, 2021
End Date	Nov 09, 2021
Duration	167 days
Number of Grantees	1
Roles	Award Holder
Data Source	Europe PMC
Grant ID	`NIHR134168`

Grant Description

To appraise the clinical and cost effectiveness of ciltacabtagene autoleucel within its marketing authorisation for relapsed or refractory multiple myeloma.